Print

AVEG 003A

A Phase I Multicenter, Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) October 30, 1990
VaxSyn gp160 Vaccine (MicroGeneSys) Env gp160 B LAI
VaxSyn gp160 Vaccine (MicroGeneSys) Protein
USA 30
NCT00000757
http://clinicaltrials.gov/ct2/show/NCT00000757